Back to Search
Start Over
Strategies for targeting the androgen receptor axis in prostate cancer.
- Source :
-
Drug discovery today [Drug Discov Today] 2014 Sep; Vol. 19 (9), pp. 1493-7. Date of Electronic Publication: 2014 Aug 10. - Publication Year :
- 2014
-
Abstract
- Androgen receptor (AR) signaling plays a critical role in prostate cancer cell proliferation, survival, and differentiation. Therapeutic strategies targeting the androgen receptor have been developed for the treatment of metastatic hormone-naïve prostate cancer; however, despite effective targeting recent studies have demonstrated that during progression to a castrate-resistant phenotype there is restoration of AR target gene expression. On the basis of this observation, second-generation therapeutics have been developed to target AR in the castrate-resistant setting resulting in a survival benefit. In this review we will discuss the mechanisms promoting AR signaling and the development of second-generation therapeutics targeting AR in castrate-resistant prostate cancer.<br /> (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Subjects :
- Animals
Antineoplastic Agents pharmacology
Disease Progression
Drug Design
Gene Expression Regulation, Neoplastic
Humans
Male
Prostatic Neoplasms, Castration-Resistant genetics
Prostatic Neoplasms, Castration-Resistant pathology
Receptors, Androgen genetics
Receptors, Androgen metabolism
Signal Transduction drug effects
Androgen Receptor Antagonists pharmacology
Prostatic Neoplasms, Castration-Resistant drug therapy
Receptors, Androgen drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1878-5832
- Volume :
- 19
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Drug discovery today
- Publication Type :
- Academic Journal
- Accession number :
- 25107669
- Full Text :
- https://doi.org/10.1016/j.drudis.2014.07.008